A Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Precancerous Lesions and Malignancies
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2017
At a glance
- Drugs INO 3106 (Primary) ; INO 9012 (Primary)
- Indications Head and neck cancer; Human papillomavirus infections; Lung cancer
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 22 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 20 Nov 2014 This trial will support an application for orphan drug status, if successful.
- 23 Sep 2014 New trial record